Unique ID issued by UMIN | UMIN000009348 |
---|---|
Receipt number | R000010980 |
Scientific Title | Evaluation of efficacy of improved nutrition for patients with head and neck cancer underwent oral nutritional supplements. |
Date of disclosure of the study information | 2012/11/17 |
Last modified on | 2015/09/11 10:37:46 |
Evaluation of efficacy of improved nutrition for patients with head and neck cancer underwent oral nutritional supplements.
Evaluation of efficacy of improved nutrition for patients with head and neck cancer underwent oral nutritional supplements.
Evaluation of efficacy of improved nutrition for patients with head and neck cancer underwent oral nutritional supplements.
Evaluation of efficacy of improved nutrition for patients with head and neck cancer underwent oral nutritional supplements.
Japan |
Head and neck cancer
Oto-rhino-laryngology |
Malignancy
NO
To evaluate a correlation between the dosage of enteral nutrition formula and body weight reduction rate, and effect of nutritional supplement consumption for patients with head and neck cancer. To analyze a relationship between the change rate of each body composition factor and the adverse events as a secondary endpoint.
Safety,Efficacy
Rate of change of body weight.
Dose of oral nutritional supplements per body weight.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
RACOL-NF Liquid for Enteral Use
20 | years-old | <= |
75 | years-old | >= |
Male and Female
1.Patients who will receive any one of the following 3 therapies: chemotherapy, radiation therapy, or chemoradiotherapy.
2.Patients who have been diagnosed and informed of diagnosis with head and neck cancer.
3.Patients who have been judged to be a candidate of oral intake by the investigator.
4.Patients aged 20 years old and older and 75 years old and under.
5.Patients and legal representative who have given voluntary written informed consent.
1.Patients who have a history of hypersensitivity to enteral nutritional supplements.
2.Patients with ileus.
3.Patients without an enteric function.
4.Patients with severe liver failure and/or renal failure.
5.Patients with abnormal glucose metabolism such as severe diabetes.
6.Patients with inborn error of amino acid metabolism.
7.Patients who had blood transfusion within one month.
8.Patients with active infection.
9.Patients with severe organ failure.
10.Patients who have edema at the time of registration.
11.Patients with electric implantable devices such as pacemakers.
12.Patients who are pregnant, suspected to be pregnant or breastfeeding.
13.Patients judged to be inappropriate for the study by the investigator.
30
1st name | |
Middle name | |
Last name | Hiroyuki Tsuji |
Kanazawa Medical University
Department of Otorhinolaryngology-Head and Neck Surgery
1-1 Daigaku Uchinada Kahoku Ishikawa
076-286-2211
tsujih-i@kanazawa-med.ac.jp
1st name | |
Middle name | |
Last name | Kanako Teraguchi |
Kanazawa Medical University
Department of Otorhinolaryngology-Head and Neck Surgery
1-1 Daigaku Uchinada Kahoku Ishikawa
076-286-2211
kanako-y@kanazawa-med.ac.jp
Kanazawa Medical University
Kanazawa Medical University
Self funding
NO
2012 | Year | 11 | Month | 17 | Day |
Unpublished
Completed
2012 | Year | 08 | Month | 15 | Day |
2012 | Year | 11 | Month | 19 | Day |
2012 | Year | 11 | Month | 17 | Day |
2015 | Year | 09 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010980